EA-230 /kg/hour

Phase 3Small molecule

EA-230 /kg/hour is one of 4 small molecule programs targeting Coronary Artery Disease (CAD). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery Disease (CAD)Not yet recruiting

Coronary Artery Disease (CAD)Phase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Coronary Artery Disease (CAD)

#DrugCompanyPhaseTrials

EA-230 /kg/hour

EEBI Anti Sepsis BV

Phase 3

1 2

Duragesic

CCephalon

Preclinical

1 3

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 4

Optimal Medical Therapy

HHelios Health Institute GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Coronary Artery Disease (CAD)

NCT07357675

Clinical

Trials by Indication[1]

Coronary Artery Disease (CAD)1 trial

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

Not yet recruiting·EEBI Anti Sepsis BV·Phase 3·NCT07357675·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EA-230 /kg/hour. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EA-230 /kg/hour compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EA-230 /kg/hour. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EBI Anti Sepsis BV company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEBI Anti Sepsis BV

EA-230 /kg/hour

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Coronary Artery Disease (CAD)1 trial

References

Drug Info

Quick Facts

Related News